个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ ESCI

作者：
Chinese Society of Clinical Oncology Breast cancer committee[1] ; Chinese Anti-Cancer Association[1] ; Committee of Breast Cancer Society[1] ; Li, Jianbin[1] ; Wang, Xiaojia[2] ; Wang, Shusen[3] ; Wang, Shu[4] ; Wang, Tao[1] ; Liu, Yueping[5] ; Geng, Cuizhi[5] ; Jin, Feng[6] ; Yin, Yongmei[7] ; Zhang, Qingyuan[8] ; Song, Erwei[9] ; Wu, Jiong[10] ; Jiang, Zefei[1] ; Chen Zhanhong[11] ; Cheng Jing[12] ; Cui Shude[13] ; Fan Zhimin[14] ; Feng Jifeng[15] ; Fu Peifen[16] ; Huang Jian[17] ; Jiang Jun[18] ; Jiang Hongchuan[19] ; Li Man[20] ; Li Xingrui[21] ; Li Hongyuan[22] ; Liao Ning[23] ; Liu Jian[24] ; Liu Qiang[25] ; Liu Yinhua[26] ; Liu Yunjiang[27] ; Liu Zhenzhen[13] ; Nie Jianyun[28] ; Ouyang Quchang[29] ; Pan Yueyin[30] ; Pang Da[31] ; Ren Guosheng[22] ; Shao Zhimin[32] ; Song Erwei[25] ; Sun Gang[33] ; Sun Tao[34] ; Tang Jinhai[35] ; Tong Zhongsheng[36] ; Teng Yuee[37] ; Wang Haibo[38] ; Wang Jiandong[39] ; Wang Kun[23] ; Wang Xiang[40] ; Wang Xin[40] ; Wang Yongsheng[41] ; Wu Jiong[32] ; Xu Binghe[40] ; Yan Min[13] ; Yan Ying[42] ; Yang Jing[43] ; Yin Yongmei[35] ; Yu Zhigang[44] ; Yuan Peng[40] ; Zhang Bin[34] ; Zhang Jianguo[45] ; Zhang Jin[36] ; Zhang Pin[40] ; Zhang Qingyuan[31] ;
机构： [1]Peoples Liberat Army Gen Hosp, Med Ctr 5, Senior Dept Oncol, Beijing, Peoples R China [2]Univ Chinese Acad Sci, Canc Hosp, Dept Breast Canc, Hangzhou, Peoples R China [3]Sun Yat Sen Univ Canc Ctr, Dept Oncol, Guangzhou, Peoples R China [4]Peoples Hosp Peking Univ, Dept Breast Surg, Beijing, Peoples R China [5]Hebei Med Univ, Affiliated Hosp 4, Shijiazhuang, Hebei, Peoples R China [6]China Med Univ, Affiliated Hosp 1, Dept Breast Surg, Shenyang, Peoples R China [7]Jiangsu Prov Peoples Hosp, Dept Oncol, Nanjing, Peoples R China [8]Heilongjiang Prov Canc Hosp, Dept Oncol, Harbin, Peoples R China [9]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China [10]Fudan Univ, Canc Hosp, Shanghai, Peoples R China [11]Zhejiang Provincial Cancer Hospital [12]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology [13]Henan Cancer Hospital [14]The First Hospital of Jilin University [15]Jiangsu Cancer Hospital [16]The First Affiliated Hospital of Zhejiang University [17]The Second Affiliated Hospital of Zhejiang University School of Medicine [18]The First Affiliated Hospital Affiliated to Army Medical University [19]Beijing Chaoyang Hospital Affiliated to Capital Medical University [20]The Second Affiliated Hospital of Dalian Medical University [21]Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology [22]The First Affiliated Hospital of Chongqing Medical University [23]Guangdong Provincial People’s Hospital [24]Fujian Cancer Hospital [25]Sun Yat-sen Memorial Hospital of Sun Yat-sen University [26]Peking University First Hospital [27]The Fourth Hospital of Hebei Medical University [28]Yunnan Cancer Hospital [29]Hunan Cancer Hospital [30]The First Affiliated Hospital of University of Science and Technology of China [31]Heilongjiang Cancer Hospital [32]Fudan University Shanghai Cancer Center [33]Xinjiang Medical University Cancer Hospital [34]Liaoning Cancer Hospital [35]Jiangsu Provincial People’s Hospital [36]Tianjin Medical University Cancer Institute & Hospital [37]The First Affiliated Hospital of China Medical University [38]Affiliated Hospital of Qingdao University School of Medicine [39]First Medical Center of PLA General Hospital [40]Cancer Institute and Hospital, Chinese Academy of Medical Sciences [41]Shandong Cancer Hospital [42]Beijing University Cancer Hospital [43]The First Affiliated Hospital of Xi’an Jiaotong University [44]The Second Hospital of Shandong University [45]The Second Affiliated Hospital of Harbin Medical University
出处：
DOI： 10.21037/tbcr-22-48

关键词： Human epidermal growth factor receptor 2 (HER2) breast cancer consensus low expression

摘要：
Human epidermal growth factor receptor 2 (HER2) is an important driver gene and prognostic indicator of breast cancer and also a key predictor of HER2-targeted therapies. The emerging anti-HER2 drugs have greatly changed the diagnosis and treatment modalities of breast cancer and dramatically improved the prognosis of HER2-positive breast cancer patients. To optimize the treatment of HER2 breast cancer an update of expert consensus on HER2 positive breast cancer was made to adjust the different recommendation levels from early stage to metastatic stage. Meanwhile, antibody-drug conjugate (ADC) like trastuzumab deruxtecan (T-Dxd) has been shown to have great efficacy in HER2-positive and HER2 low expression breast cancer patients. Clinically, on the basis of the original definition for HER2-negative breast cancer, patients with HER2 immunohistochemistry (IHC) 1+ or IHC 2+ and in-situ hybridization (ISH)-negative are defined as low HER2 expression (HER2-low). As both the low expression and the positive expression of the HER2 protein is clinically significant for disease treatment and prognosis, we added a new chapter of HER2 low to recommend a proper regimen for this kind of patients. In this consensus, we also talk about the importance of clinical research, real world evidence, biosimilars and so on. In addition, the whole-course management of HER2 breast cancer is even more critical during pandemic of coronavirus disease 2019 (COVID-19). An approach that gives preference to "low-toxicity regimens and oral preparations" are also recommended.

语种：
外文
被引次数：
WOS：
PubmedID：
第一作者：
第一作者机构： [1]Peoples Liberat Army Gen Hosp, Med Ctr 5, Senior Dept Oncol, Beijing, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Chinese Society of Clinical Oncology Breast cancer committee,Chinese Anti-Cancer Association,Committee of Breast Cancer Society,et al.Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)[J].TRANSLATIONAL BREAST CANCER RESEARCH.2022,3:doi:10.21037/tbcr-22-48.
APA：
Chinese Society of Clinical Oncology Breast cancer committee,Chinese Anti-Cancer Association,Committee of Breast Cancer Society,Li, Jianbin,Wang, Xiaojia...&Zhang Qingyuan.(2022).Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition).TRANSLATIONAL BREAST CANCER RESEARCH,3,
MLA：
Chinese Society of Clinical Oncology Breast cancer committee,et al."Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)".TRANSLATIONAL BREAST CANCER RESEARCH 3.(2022)

相关文献

[1]More than 14 years' progress free survival of neratinib monotherapy for human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer: a case report [2]Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients. [3]Pathological precision diagnosis and recent advances in HER2 low and ultralow in breast cancer: a narrative review [4]Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) [5]To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer [6]Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer [7]乳腺微乳头状癌的临床病理特征分析 [8]Recent advances and updated highlights in breast cancer pathologic diagnosis: a narrative review [9]A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma [10]HER2-low breast cancer: insights on pathological testing

资源点击量：39767 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号